Richard P. Bryce's most recent trade in enGene Holdings Inc was a trade of 153,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Nov. 30, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| enGene Holdings Inc | Richard P. Bryce | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2023 | 153,000 | 153,000 | - | - | Stock Option (Right to Buy) | |
| Rain Oncology Inc | Richard P. Bryce | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 110,000 | 110,000 | - | - | Stock Option (Right to Buy) | |
| Rain Oncology Inc | Richard P. Bryce | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 53,064 | 53,064 | - | - | Stock Option (Right to Buy) | |
| Puma biotech Inc | Richard P. Bryce | SEE REMARKS | Sale of securities on an exchange or to another person at price $ 9.80 per share. | 05 Apr 2021 | 426 | 121,662 (0%) | 0% | 9.8 | 4,176 | COMMON STOCK |